• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Strategies for treatment of disease-associated dementia beyond Alzheimer disease: An update
Curr Neuropharmacol. 2022 Apr 11. doi: 10.2174/1570159X20666220411083922. Online ahead of print.ABSTRACTMemory, cognition, dementia, and neurodegeneration are complexly interlinked processes through various mechanistic pathways leading to a range of clinical outcomes. These are strongly associated with pathological conditions like Alzheimer's disease, Parkinson's disease, schizophrenia, stroke and are a growing concern for their timely diagnosis and management. Several cognition-enhancing interventions for management include non-pharmacological interventions like diet, exercise, and physical activity, while pharmacological...
Source: Current Neuropharmacology - April 12, 2022 Category: Drugs & Pharmacology Authors: Khan Sabiya Samim Gopal L Khatik Ashok K Datusalia Source Type: research

Chinese Herbal Medicine Interventions in Neurological Disorder Therapeutics by Regulating Glutamate Signaling.
Abstract Glutamate is the major excitatory neurotransmitter in the central nervous system, and its signaling is critical for excitatory synaptic transmission. The well-established glutamate system involves glutamate synthesis, presynaptic glutamate release, glutamate actions on the ionotropic glutamate receptors (NMDA, AMPA, and kainate receptors) and metabotropic glutamate receptors, and glutamate uptake by glutamate transporters. When the glutamate system becomes dysfunctional, it contributes to the pathogenesis of neurodegenerative and neuropsychiatric diseases, such as, Alzheimer's disease, Parkinson's disease...
Source: Current Neuropharmacology - October 31, 2019 Category: Drugs & Pharmacology Authors: Liu Y, Wang S, Kan J, Zhang J, Zhou L, Huang Y, Zhang Y Tags: Curr Neuropharmacol Source Type: research

One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke.
Abstract Tissue plasminogen activator (t-PA) is the only FDA approved drug for acute ischemic stroke treatment, but its clinical use is limited due to the narrow therapeutic time window and severe adverse effects, including hemorrhagic transformation (HT) and neurotoxicity. One of the potential resolutions is to use adjunct therapies to reduce the side effects and extend t-PA's therapeutic time window. However, therapies modulating single target seems not satisfying, and a multi-target strategy is warranted to resolve such complex disease. Recent years, large amounts of efforts have been made to explore the active...
Source: Current Neuropharmacology - June 18, 2016 Category: Drugs & Pharmacology Authors: Chen HS, Qi SH, Shen JG Tags: Curr Neuropharmacol Source Type: research